Pace Cme - Practical experience and model for optimizing.

PCSK9: Outcomes and trials in clinical perspective There is still a high (residual) risk for future events in many high risk ASCVD patients, despite maximally tolerated statin therapy. 001), compared to randomization to avoid caffeinated products. What are potential mechanisms that may explain the benefits observed with icosapent ethyl? Prof. 13, 2023 Presented at the ESC congress 2023 by: George Bakris, MD - Chicago, IL, USA Introduction and methods Zilebesiran is a RNA interference therapeutic that inhibits the synthesis of hepatic angiotensinogen. family AND "Lou Manousos" One of the key advantages of using Medscape CME. AHA 2023 As discussant of the SELECT trial, Ania Jastreboff reviews the results. Subtitles available: English, French, German & more. However, the choice of anticoagulant used by each center (unfractionated heparin, enoxaparin, or bivalirudin) could have influenced the 30-day ischemic outcome. Part Two of the ‘NLA recommendations for patient-centered …. Literature - Sharma M, Hart RG, Connolly SJ et al. Apr 4, 2024 · PACE CME Courses. Prolonged Anticoagulation After Primary PCI for STEMI Does Not Reduce Ischemic Events. Lessons from the biology of CETP inhibition. Listen to/watch this animated podcast!. CME's PRO TV sets the pace in #Romania · CME's Pro TV sets the pace in Romania. Raul Santos and Maciej Banach talk about the safety of PCSK9 mAbs and of very low cholesterol levels, and discuss the importance of patient education to improve adherence. The Imminent danger of Lp (a): Time to face to challenge. Further research should shed light on whether low-grade inflammation mediates the association between diet and the development of type 2 diabetes. Hyperkalemia drives suboptimal use of RAASi therapy, which is associated with increased CV risk in HF patients. Solomon summarizes the results of the DELIVER trial. 5% that economists were predicting and the fastest pace in a year. The VICTORION-INITIATE was a prospective, randomized, open-label, phase 3b trial enrolling 450 patients with a history of ASCVD, …. In the phase 2b study, the effect of …. Understanding the working mechanism of EPA. dr sebi daughter usha website warfarin for stroke prevention in patients with atrial fibrillation (AF) showed that DOACs are as effective as warfarin in …. Atherogenic dyslipidemia increases CV risk in diabetes patients. p>This summary is based on the presentation of James Januzzi Jr. 27, 2023 Presented at the ESC Congress 2023 by: Milton Packer, MD - Dallas, TX, USA Introduction and methods It is usually recommended that the foundational HF medications need to be taken indefinitely by patients who can tolerate these medications. Diabetic nephropathy is one of the leading causes of ESRD. Lessons from a trial with colchicine in patients undergoing thoracic surgery. no audio connection for fm honda odyssey Not only to achieve weight reduction, but also to improve health outcomes. Cancer mortality rates are 15%, 30% and 55% for LIC, MIC and HIC, respectively. Continuing medical education is a specific form of continuing education that helps healthcare professionals maintain their competences. cjc ram 2500 She points out that it is critical to treat obesity. Clinically meaningful outcomes were seen, including a 10 mmHg lower SBP, which is associated with risk reductions of 20% of CVD events, 17% CHD, 27% stroke and 13% all-cause mortality. A similar finding was observed when DHA was adjusted for EPA and comorbidities. Learn from expert faculty and …. - Our reporting is based on the information provided at the AHA Scientific. Naveed Sattar, MD, PhD (Glasgow, UK) presented SURMOUNT-4 background, rationale design and baseline characteristics, and Louis Aronne, MD (New York, NY, USA) presented SURMOUNT-4 study efficacy and safety results. tippah county news today They show beneficial effects of SGLT2 inhibitors in patients with CKD and as a result the KDIGO guidelines were updated in 2022 to include this new evidence. Where do novel therapies targeting the PCSK9 pathway might fit in with regard to the lipid management paradigm? Ann Marie Navar gives an overview on current and future therapies. Icosapent ethyl has been indicated as an adjunct to maximally tolerated statin therapy in adults with elevated triglyceride levels and CVD or DM with at least two additional CV risk factors to reduce risk of CV events. Challenges in ASCVD reduction and TG-related risk. Completing prerequisite coursework for advanced cardiac life support certification results in the receipt of eight continuing education units, or CEUs. Introduction and methodsIt has been clearly demonstrated that treatment with lipid lowering agents reduces the risk of atherosclerotic CV events [1-4]. 16, 2023 Presented at the EASD annual meeting 2023. The increase in prescription of GLP-1RA remained lower (4% in 2016 to 15% in 2021). The percentage of patients with increased fibrous cap was 80% at 26 weeks. This program uses hands-on, interactive, personalized and didactic instruction. A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy. New LendingTree data shows that businesses are starting in the US at a record pace in 2020. 24 Scientific Session - The Diabetes Remote Intervention To Improve Use Of Evidence-based Medications (drive) Study: A Randomized Evaluation Of A Team-based Remote Education And Medication Management Program To Reduce Cv And …. In patients with apparent resistant hypertension, sacubitril/valsartan reduced SBP to a greater extent than valsartan. New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D. Avoidance of Deficiencies in the Medical Record. ibio after hours In this educational program, three experts discuss the clinical characteristics and pathophysiology of HCM, challenges in the diagnosis and management, and therapeutic options for patients with …. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for . This phase 1 single ascending dose study showed that subcutaneous injection of SLN360, an siRNA targeting mRNA for the LPA gene, lowered Lp (a) up to 98%. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl. This pooled analysis of ORION-9, ORION-10 and ORION-11 showed that inclisiran administered subcutaneously twice-yearly reduced LDL-c on average by 50. What is the mechanism of action resulting in benefit with SGLT2i? Carlos Santos-Gallego discusses the results of the EMPA-TROPISM trial that shows reverse LV remodeling by empagliflozin in non-diabetic HFrEF. Literature -Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High-Dose Statin TherapyRaal F, Panz V, Immelman A, Pilcher GJ Am Heart Assoc. The phase 3 OASIS 1 trial showed that oral semaglutide 50 mg once daily led to a placebo-adjusted mean weight reduction of 13% at 68 weeks in adult patients with overweight or obesity but no T2DM. The present study identified and validated a metabolic signature reflecting adherence to a Mediterranean diet and examined whether this signature was associated with CVD risk. Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients? Prof. Primary care role in CKD - PACE-CME. Funding for this educational program was provided by unrestricted educational grants from Amgen & Novo Nordisk A/S. In this series, three experts discuss the reasons and clinical consequences of suboptimal RAASi therapy in patients with HF, and focus on how to solve issues with hyperkalemia. Implementing precision health for public health using causal AI. In the past, there has been confusion about the relationship between HDL-c and CV risk and also between triglycerides and CV risk. craigslist in st joe missouri In August 2021, empaglifozin had been approved by the FDA to reduce the risk of CV death and HF hospitalization for adult with HF. - Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn. Two experts discuss recent clinical trials of long-term IV iron therapy in patients with heart failure and iron deficiency and talk about how the results of these trials can be translated into daily practice. Apr 6, 2023 · During the last few years, results of the first dedicated kidney trials with SGLT2 inhibitors –CREDENCE, DAPA-CKD and EMPA-KIDNEY– were presented and published. Unexpected findings when comparing DOAC with VKA in rheumatic AF. AHA 2023 ESC Congress 2023 EAS 2023 ESC Heart Failure 2023 ACC. Evidence suggests an important role. Kuiper Distinguished Professor of Medicine, Emeritus Professor of Medicine and of Pharmacology and Physiology at the University of Rochester in. These patients have poor outcomes and treatment options are very limited. Introduction and methods Patients after acute MI (AMI) are at higher risk to develop HF. - Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease. These observations are consistent with prior population-based data on fasting. The role of ALP as predictor of CV events and vascular calcification in CKD. Next to statins, ezetimibe and bile acid sequestrants (BAS) are attractive therapeutic options for cardiovascular disease (CVD) prevention, specifically in patients with hyperlipidemia who are unable to reach defined lipid targets with statin alone, or in patients with poor tolerance to statins. Study with traditional Chinese medicine in HFrEF: what's the next step? ESC Congress 2023 Juan Pablo Kaski talks about some of the highlights of the ESC guidelines on cardiomyopathies with regard to the phenotype-specific management of cardiomyopathies. 7% with placebo, 25 mg QD, 25 mg BID, 50 mg BID, 100 mg BID and 200 mg BID, respectively. Introduction and methods Background and aim of the …. Many etiologies have been discovered since the beginning of the description of HCM. 29, 2022Presented at the ESC congress 2022 by: Marco Valgimigli, MD, PhD – Lugano, SwitzerlandIntroduction and methodsThe investigators searched for studies comparing aspirin with any P2Y12 inhibitor. As most people regularly consume …. The release was announced during the NLA Scientific Sessions in Chicago, IL, USA. Literature - Heerspink HJL, Jongs N, Chertow GM et al. The risk reductions were independent of T2DM, …. Binding to PCSK9 leads to blockage of the interaction between PCSK9 and the LDL receptor (LDLR), prevention of LDLR degradation, …. Intake of saturated fat, salt, and refined carbohydrates should …. Cocoa futures hit a new high in New York — topping $11,000 a metric ton — as the pace of processing in chocolate factories holds up even in the face of a global …. Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA. For a long time, there were no new developments in the field of chronic kidney disease (CKD), despite the huge burden of this disease with a high morbidity and mortality rate. More investors are swapping cryptocurrencies for stablecoins,. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by. In relatives, the Agatston scores were higher and CAD was more often associated with the presence of obstructive lesions and proximal locations compared with controls. AHA 2023 "This is such a fascinating time in lipid therapeutics," says Karol Watson. Verheugt discusses the results of prespecified analyses of the TWILIGHT trial, in those with diabetes and those with complex PCI (the TWILIGHT-COMPLEX study). CETP inhibitors: Past, present and future. BackgroundStatin therapy is central to secondary prevention after acute myocardial infarction (AMI), thus prescription of statins at discharge is highly recommended in AMI guidelines [1,2]. What are key findings of two CV outcomes trials with icosapent ethyl? Prof. The Reno County Commission approved a motion to switch the official newspaper of Reno County from the Hutchinson News to the Rural Messenger on …. It is however unknown whether SGLT2 inhibitors can be used to treat patients with HF. This study examined the outcomes of RDN in the presence of antihypertensive medication in an extension cohort in an international sham-controlled RCT. Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. Medicine Matters Sharing successes, challenges and daily happenings in the Department of Medicine Tumulty Topics in Clinical Medicine is a longstanding Department of Medicine tradi. Introduction and methods Tirzepatide is a dual GIP and …. The United Kingdom Prospective Diabetes Study (UKPDS) concluded that tight blood pressure control (BP) in patients with T2DM and hypertension can reduce macro- and microvascular diabetic complications [2]. These results suggest when EPA is combined with DHA, the net impact of higher EPA is blunted by the negative effect of DHA. ACP CME 160 allows learners to watch each lecture and claim CME credit at their own pace. Watch the other videos of this series. Funding for this educational program was provided by an unrestricted educational grant received from AstraZeneca. - Circulation 2019; Online published ahead of printIntroduction and methodsAlthough treatment with aspirin is recommended for CV prevention in individuals with atherosclerosis, aspirin reduces risk for major vascular events (myocardial infarction, stroke, or vascular death) by only 12% in primary …. Watch all episodes, answer pre- and …. In this series, three experts discuss triglyceride-related CV risk, review …. Inorganic nitrate reduces risk of contrast-induced nephropathy after coronary angiography. GLP-1RAs may result in beneficial effects on renal outcomes, as shown by analyses of secondary endpoints in large trials. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME. You can access free online assessments, earn credits, and track your certificates …. Press cancel to remain on PACE-CME. Sabatine highlights subgroups of high-risk patients who benefit most from treatment with this PCSK9 inhibitor. ®) is an administrative system serving as the quality assurance mechanism for continuing education programs …. The change in name reflects the fact that this course has always sought to assist healthcare providers manage high impact. Learning Objectives Educational Objectives Recognize clinical scenarios indicative of the need for an HCM-specific therapeutic approach Evaluate the most recent clinical data on the. PACE Small Group Remedial CME Since 1996, PACE has been providing small group remedial CME. Novel RNAi therapeutic lowers blood pressure in patients with hypertension. Cunningham is a city in Kingman County, Kansas, United States. ARUP Laboratories offers free online continuing education courses for clients, physicians, and laboratory professionals in various specialties. A mechanism of action animation of SGLT2-inhibition, a diabetes therapy that directly targets glucose by reducing renal glucose reabsorption, independently of beta cell function and insulin resistance. clayton homes land packages Monitoring location 07144780 is associated with a Stream in Reno County, Kansas. Meeting report with presentation slides, videos and online CME of the EBAC-accredited symposium held at ESC Preventive Cardiology 2023, Malaga, Spain. harry potter fanfiction lemons This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in …. Levels of triglycerides and high-density lipoprotein cholesterol were unchanged. Atrial fibrillation: From risk prediction to clinical outcomes. A total of 714 participants were first randomized to receive either empagliflozin 10 mg or placebo for 8 weeks, they. - Microplastics and Nanoplastics in Atheromas and Cardiovascular Events. Updates in anticoagulation management in AF and VTE. LabCE offers American Society of Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education® (P. Literature - Chant B, Bakali M, Hinton T, et al. ESC Congress 2023 "Ferric carboxymaltose (FCM) should be considered as an important part of the management of patients with heart failure and concomitant iron deficiency", says Piotr Ponikowski. Join more than 155,000 actively . However, CME is deeply concerned about the pace of implementation of previously announced measures, compounded by the chilling impact on manufacturing …. Presented at the ESC congress 2023 by: Theresa McDonagh, MD - London, UK and Marco Metra, MD - Brescia, Italy. Improving quality of life in patients with HCM. 19, 2019Linagliptin and glimepiride have comparable CV safety effects in type 2 diabetes (T2DM) at high CV risk, show data of the CAROLINA trial, presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain. Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF. On day one it's slashing prices and selling smart speakers. A mechanism of action animation on the role of PCSK9 in the regulation of LDL cholesterol. The data show a new transition, towards CVD as a cause of death going down in HIC (23% in HIC, 42% in MIC and 43% in LIC). In large RCTs, PCSK9 inhibitors have shown to have great value in patients with ACS, but how do you implement these agents in clinical practice? With poll. Learning Objectives Educational Objectives Describe the impact of obesity as both an …. [Epub ahead of print] Glucose lowering and vascular benefitsThe idea that hyperglycaemia links diabetes and coronary artery disease was already hypothesised in 1929. Injection site reactions and bronchitis occurred more often in …. HFpEF: The essentials to know There are several diagnostic approaches for HFpEF. Furthermore, BP-lowering treatment resulted in a similar reduced risk among those with or without CVD and irrespective of baseline systolic BP. AHA 2021 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. org reports news from the AHA Scientific Sessions 2023 held at Philadelphia, PA, USA, Nov 11-13, 2023. RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis. Since the publication of the previous version in 2013, a lot of new evidence has become available that has implications for …. AHA 2019 The ISCHEMIA trial compared early invasive vs. continuing medical education (CME) opportunities. EASD 2022 A post hoc analysis showed that semaglutide reduces CV risk across all strata of kidney function and kidney damage in patients with T2DM who are at high CV risk. We want to be a buyer at some point but here's the rubONON On Holding AG (ONON) is a holding company and through its subsidiaries, provides footwear and sports apparel prod. Bakris, MD is Professor of Medicine and Director of the ASH Comprehensive Hypertension Center at the University of Chicago Medicine in Chicago, IL, US. 09 mmHg/year; increasing trend =-0. Select programs also carry ANCC contact hours. Verma discusses the CV results of clinical trials with GLP-1RAs and how these translate to CV protection in T2DM. Unfortunately, many patients are unable to tolerate statins or maximize statin dose resulting in a high …. Significant reductions in related lipid parameters such as non-HDL-c and total cholesterol were also seen with ETC-1002, as well as lower inflammatory. The new guidelines recommend continuing dual APT for all patients at least 1 year after DES implantation [1]. - Hypertension 2018;72:102-109Introduction and MethodsIn individuals with hypertension, the systolic blood pressure (SBP) rises extremely during exercise, which increases their risk of CV morbidity and mortality [1]. Time to reduce implementation gaps of lipid-lowering therapy. Full-dose angiotensin-converting enzyme (ACE) inhibitor and angiotensin-receptor blocker (ARB) therapy appear useful for lowering blood pressure as well as for prevention of cardiovascular (CV) events in hypertensive patients at high CV risk, including patients with obesity. The DELIVER trial was a global, event-driven, phase 3 RCT in which 6263 patients with symptomatic HFmrEF or HFpEF (LVEF >40%) were randomized to dapagliflozin 10 mg once daily or matching placebo between August 2018 and December 2020. CV risk reduction beyond statin therapy: Exploring the role of icosapent ethyl. AHA 2023 “Non-adherence is a huge problem and probably the biggest barrier when it comes to hypertension control” says Florian Rader. New insights and guidelines for the management of CKD and diabetes. health insurance company Medicare. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme. These data show that the e-counselling programme enhanced efficacy of usual care for hypertension at 12 months. Lp (a) meeting Existing clinical LDL-c assays cannot distinguish LDL-c from Lp (a)-c. The DICTATE-AHF trial was designed to examine the efficacy and safety of early in-hospital initiation of dapagliflozin when added to intravenous (IV) loop diuretics. 4 mg reduced the risk of the primary outcome of CV death, MI, or stroke by 20% in patients with pre-existing CVD and overweight or obesity, but who do not have diabetes. Having a meal before prior to MK-0616 dosing caused an attenuation of absorption and resulted in …. You are on the right webpage! The UC San Diego PACE Program is excited to announce that Anger Management for Healthcare Professionals has been changed to Managing High Impact Emotions for Healthcare Professionals (HIE). Despite the availability of effective and safer novel oral anticoagulants (NOACs), as compared with vitamin K antagonists, many high risk patients with atrial fibrillation receive inadequate anticoagulation for stroke prevention. Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice? Diabetes & CVD: Time for a multifactorial approach. Incidence rate of symptomatic ischemic stroke were 5. lexi diamond dead Pace yourself when drinking alcohol. To decrease bleeding events in …. Facebook parent company Meta Platforms Inc. News - June 30, 2021Presented at the ESC HF 2021 by Ewa Straburzynska-Migaj (Poznan, Poland)Introduction and methodsMany patients with HF also have CKD. Relative difference of -6% in the eGFR <30 group, -6% for in the eGFR ≥30 to <45 group, and -4% in the eGFR ≥45 …. ESC Congress 2023 The results of the INTERASPIRE survey call for action to improve secondary prevention of CHD globally. News - July 11, 2023 The US Food and Drug Administration (FDA) has approved a label update for inclisiran to include treatment of patients with elevated LDL-c who have an increased risk of heart disease, in addition to diet and statin therapy, for primary prevention of CV events. 26, 2019Presented during the AHA Scientific Sessions 2019 by John J V McMurray, (University of Glasgow, Glasgow, United Kingdom). Programs; Live Events; About Us; Newsletter Subscription; We’re glad to see you’re enjoying PACE-CME. In the FOURIER trial, therapy with. 1093/ehjopen/oead114 Introduction and methods Background Patients with …. Well-designed EHR tools can improve prescribing of MRA in HFrEF. 23 Steven Nissen summarizes the results of the CLEAR Outcomes trial and explains what impact these …. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. Hereby, we aim to stimulate the review, exchange and assimilation of key . News - May 19, 2021A Novel Physical Rehabilitation Intervention for Older Patients with Acute Decompensated Heart Failure: The REHAB-HF TrialPresented at ACC. Reducing cardiovascular risk in diabetes: The next preventive challenge. Three speakers discuss the players in residual risk with a focus on triglycerides. 4 mg Once-weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction, and Type 2 Diabetes) trial was an international, multicenter, double-blind, placebo-controlled, phase 3 RCT in which 616 patients with HFpEF (LVEF ≥45%, NYHA …. Asking prices for UK homes rose at the highest annual pace in 12 months, driven by more top-of-the-ladder houses coming to market, according to the online sales portal Rightmove. Nissen said that these findings support further development. The phase 2 trial BrigHTN demonstrated …. The latest evidence of SGLT2i in CKD. AHA 2023 What are the long-term effects of a postpartum physician-guided BP lowering strategy in women after hypertensive pregnancy? Paul Leeson shares the results of the POP-HT trial. SGLT2i: Overview of recent trials and guideline recommendations. Your professional development is critical to the care of your patients. Literature - Barnett AH, Huisman H, Jones R, et al. 7, 202314-week phase II data showed a significant reduction of albuminuria of up to 39. 28, 2023Presented at the ESC Congress 2023 by: Linda Joosten, MD - Utrecht, The NetherlandsIntroduction and methodsThe frailty syndrome is not just defined by high age, but also by the combination of having multiple diseases, taking a lot of medications, a high dependency on others and a reduced capacity to resist stressors. John McMurray, MD – Glasgow, UKIntroduction and methodsThere was a concern that sacubitril/valsartan might impair cognitive function. Novel insights in inflammatory makers, AI, …. 4, 2023 Presented at the ESC Congress 2023 by: R. In this post-hoc analysis of the ODYSSEY OUTCOMES trial, post-ACS patients who achieved LDL-c <0. Staging therapy in HCM patients with heart failure: New insights. Learn from expert faculty and contributors at the University of Utah School of Medicine and ARUP Institute for Learning. This approval is based on findings in the_HAUSER-RCT_phase 3b trial , in which the safety and efficacy of evolocumab was examined in pediatric patients, 10-17 of age, with. The team of Kronenberg discovered a mutation in the Kringle-IV type 2 region of Lp(a), which has a modifying effect on Lp(a) levels and CVD risk. Treatment goals for patients with T2DM and CKD. The Insider Trading Activity of Pace Nicholas J on Markets Insider. Partners for Advancing Clinical Education (PACE) Provider Information. What is the evidence of SGLT2i in CKD? 4 things to know about CKD and SGLT2i Prof. 09:45 - 10:30 WEST We’re glad to see you’re enjoying PACE-CME. Equity Quarterly Roll Analyzer Tool. Diabetes is a major risk factor in HF and is strongly linked to progression of the disease. However, patients with eGFR<45 mL/min/1. This phase IV trial compared four RAAS inhibitors, among which two ACE. There was a positive association for each 1 g increase in sodium intake and the mean overall CV event rate (0. Zannad presents trial results with the new potassium binders ZS-9 and patiromer. In this pooled analysis of the SUSTAIN studies, the efficacy. 0010) and 36 less minutes sleep per night (95%CI 22-50, P<0. In the elderly (≥75 years), the rates of stroke/SSE were similar with edoxaban and warfarin (HR: 0. You can access free online assessments, earn credits, and track your certificates on the PACE Learner Experience Portal. CME Group's (CME) charts are pointing to a bullish future for the shares despite a recent decline, as buyers of the exchange operator's stock have been aggressive over the. Targeting Lp (a) in CV risk reduction: where are we now? Prof. 29, 2020The REDUCE-IT trial previously showed a 25% overall event reduction of the primary endpoint (CV death, MI, stroke, coronary revascularization, unstable angina) in statin-treated patients randomized to icosapent ethyl (IPE), compared with those randomized to placebo. Five years of PCSK9i - Lessons from practice: Which patients benefit most? Prof. 118 freeway closure today 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The CKD components as well as the cardiovascular components of the primary endpoint contributed to the risk reduction. The percentage of patients with FCT <65 µm decreased from 48% to 13%. 6, 2022Presented at the AHA Scientific Sessions 2022 by: Paul R. PACE INSTITUTE OF TECHNOLOGY AND SCIENCES (PACE PACE INSTITUTE OF TECHNOLOG. What is the best antithrombotic treatment post-PCI? ESC Congress 2023 A one-size-fits-all approach is used with regard to loop diuretic therapy in patients with acute HF, although guidelines highlight the importance of early diuresis. The startup investing market is crowded, expensive and rapid-fire today as venture capitalists work to preempt one another, hoping to deploy funds into hot companies before their c. She substantiates this by summarizing three late-breaking science studies with VERVE-101, lepodisiran and recaticimab. Literature - Raal F, Durst R, Bi R, et al. 23 Treatment with anthracyclines may lead to cardiotoxicity. These data support calls for population-wide intervention to reduce dietary salt intake, not only for its beneficial effect on renal/CV morbidity/mortality, but also for its beneficial effect on therapy response to RAAS intervention. The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change. AHA 2023 Michael Lincoff focusses in this video on the clinical implications of the results of the SELECT trial. Dialogue on how to overcome clinical inertia with regard to SGLT2i. okta inspire brands 6 years, compared with placebo, are sustained or enhanced for at least 3 years after stopping therapy in individuals without CVD but at intermediate risk for CV events. News - May 25, 2023Presented at the ESC Heart Failure 2023 by: Ross Campbell, PhD - Glasgow, UKIntroduction and methodsIn patients with HF, diuretic resistance is associated with worse clinical outcomes. Use of anthracyclines is associated with cardiac injury and an increased risk of heart failure. Ray focuses on micro- and macrovascular disease in type 2 diabetes, their implications, their interrelationship and how these risks can be modified by new glucose-lowering agents. Mikhail Kosiborod presents a case of a 50-year-old patient with T2D, obesity, symptomatic HFpEF and early-stage CKD. The meta-analysis of the DAPA-HF and EMPEROR-Reduced trials revealed that SGLT2 inhibition combined with standard HF care in HFrEF patients reduced all-cause mortality and CV death, HF hospitalization and serious adverse renal events, without any heterogeneity between the two trials. Patients with and without T2DM were included and all patients were on stable ACEi or ARB treatment. 24 - Michael Gibson shares the results of the AEGIS-II trial, in which infusions of human ApoA-1 - the building block of HDL-c - with CSL112 in the first month after an MI did not improve CV mortality, MI or stroke at 90 days. Brandenburg explains how BET inhibition can interfere with factors and pathways associated with vascular calcification. 1056/NEJMoa2309822 Introduction and methods Background Recent preclinical studies (in human cells or tissues and animal …. Stay on top of the latest treatments and information with ReachMD's CME activities. How will outcomes of ARNI trials impact diagnosis and management of HF? The co-chairs introduce the topic of this symposium by explaining that many novel therapies for HFrEF have resulted in difficulties in decision-making for management of these patients. In this educational program, three experts discuss the clinical characteristics and pathophysiology of HCM, challenges in the diagnosis and management, and therapeutic options for patients with HCM. Jeffrey Pace, Software Applications Developer IV, was honored with the 2024 President's Meritorious Service Award for his outstanding contributions to the university. The results for diastolic BP (DBP) were similar. The number of participants alive at each year of age is represented by the n at risk. Invitation to the EBAC-accredited satellite symposium on ‘The Weight of Cardiovascular Risk: Addressing Obesity in Cardiac Patients’, at ESC Preventive Cardiology Congress 2024, Athens, Greece. This course consists of 4 episodes. Even after reaching LDL-c targets, residual CV risk can remain high. Additionally, they present data of the REDUCE-IT trial with icosapent ethyl and provide guidance for implementation of icosapent ethyl in the management of patients with residual risk. Our objective is "CME that matters". “Walk faster, please” I mutter to him. For more information, please visit the ESC website. Read our summary of the recombinant fusion protein The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change. 24 AHA 2023 ESC Congress 2023 EAS 2023 ESC Heart Failure 2023 …. Continuing Medical Education (CME) is the mechanism for the life long learning requirement for every healthcare professional. ®) is an administrative system serving as the quality assurance mechanism for continuing education programs offered to clinical laboratory professionals. the greatest estate developer chapter 99 A vegetarian diet was defined as a diet generally excluding or rarely including meats. Explore topics such as dyslipidemia, HCM, ASCVD, and more with experts and case studies. This recording was independently developed under auspices of PACE-cme. In 2010, the completion of the IMPROVE-IT trial was pushed back from 2012 to June 2013, while last year the DSMB …. They show beneficial effects of SGLT2 inhibitors in. Armitage presents a study in which this was investigated using data of the ASCEND trial. 28, 2022Presented at the ESC congress 2022 by: Prof. PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities. cream d mint strain California Medical Board approved CME course. greyhound bus phone number near me News - June 22, 2015The National Lipid Association (NLA) has released a draft of new recommendations for cholesterol management, focussing on diverse ethnic and racial groups and all age groups. The DAPA-CKD trial was a double-blind, randomized, placebo-controlled trial of 4304 patients with CKD, defined as an eGFR of 25-75 mL/min/1. Potassium intake was not significantly associated with SBP or DBP. Those with EPA/DHA ≤1 had a 10-year MACE of 37% …. ESC 2017 Peter Libby, who started basic research on the role of IL-1 in atherogenesis 30 years ago, gives his perspective on the CANTOS results, including the preliminary results that hint at a reduction in cancer fatalities. The aim of the study was to determine whether the coexistence of AF at. - J Am Coll Cardiol 2017;70:2841–8BackgroundThe Dietary Approaches to Stop Hypertension (DASH) and the DASH-Sodium trials showed that a DASH diet rich in fruits, vegetable, and low-fat dairy products, with reduced saturated fat and cholesterol, as well as a diet with low sodium, …. Lp(a) meeting Small isoforms of Lp(a) are associated with high Lp(a) concentrations and increased CVD risk. It is important to identify the etiology in a patient with HCM as it drives the treatment plan for these patients. However, many ACS patients do not achieve these goals on statins alone. Deepak Bhatt explore the newer cardiac myosin inhibitors that go beyond traditional medical management for the treatment of hypertrophic cardiomyopathy (HCM) at the cellular level. The prescription rates for novel glucose lowering drugs increased rapidly from 2016 to 2021 (7% in 2016 to 47% in 2021). The framework in these guidelines is used to calculate risk using the pooled …. Seven trials were identified including 35,752 individual participants from 492 sites across Asia, Europe and North-America. This progressive and fatal disease is characterized by the deposit of TTR amyloid, which consists of misfolded TTR aggregates, in the heart. Many patients need additional therapies on top of statins to lower residual CV risk. Andexanet alfa was given conditional approval for the reversal of anticoagulation in life-threatening or uncontrolled bleeding by the US Food and Drug Administration (in 2018) and European Medicines Agency (in 2019); in Japan, full market approval was obtained (in 2022). 21, 2017BackgroundMany patients with heart failure (HF) also have diabetes. masoud shojaee net worth forbes The reduction in NT-proBNP levels only explained a small part (~10%) of the effect of canagliflozin on hospitalization for HF. Milton Packer presents findings from the two major HF trials with sacubitril/valsartan, PARADIGM-HF and PARAGON-HF, and proposes that the definition of HFrEF should be changed to EF <50%. Conclusion Moderately low dietary sodium intake enhances the effect of RAAS intervention on renal and CV outcome. Jukema discusses the use of PCSK9 inhibitors in these high risk patients and the recommendations from international guidelines. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy Literature - Ridker PM, Tuttle KR, Perkovic V, et al. Eur Heart J 2016; April 26, published online ahead of print It has never been proven that non-fasting lipid profiles are non-superior over fasting lipid profiles. 4 things to know about CKD and SGLT2i. Shelley Zieroth, MD is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, and Director of the Heart Failure and Heart Transplant Clinics at St. Solomon gives a comprehensive overview of the PARAGON-HF trial and presents results of an analysis of combined data of the PARADIGM-HF and PARAGON-HF trials. 000028)BackgroundFamilial hypercholesterolemia (FH) is often …. Two cardiologists, one in an ambulatory setting and one in a hospital setting, discuss the treatment of a patient with severe heart failure following an MI over the course of two years. Nevertheless, common underlying etiology can be identified among patients with HCM. The findings of this phase 2 trial were that inhibition of factor XIa with asundexian did not reduce the primary outcome – a composite of covert brain infarction or ischemic stroke – in patients with acute, non-cardioembolic ischemic stroke. Once you have enrolled in a course (or courses), you will be contacted by a PACE representative with additional information on how to participate in your course(s. Americans were quitting at all-time highs again in November, with pandemic-h. A total of 41 patients (mean age 56 years, 59% female) with symptomatic non-obstructive HCM (NYHA class II/III, LVEF ≥ 60%, NT-proBNP >300 pg/mL) entered the study. Find out how to contact PACE, view their activities, credits, participants, and commercial support status. ETFs have inhaled more than $600. Watch another video on the guidelines by Juan Pablo Kaski Find the publication of the guidelines online at Eur Heart J. 2022 Aug 9;ehac444 [Online ahead of print]. However, there were promising trends across multiple secondary and post-hoc outcomes. Post-hoc analyses of fibrate trials suggested that TG lowering in patients with T2DM, mild-to-moderate hypertriglyceridemia and low HDL-c may be beneficial. The north fork rises in the southern part of Stafford County and flows …. Discussion: Novel opportunities tackling residual cardiovascular risk: The evolving role of triglycerides. 1, 2016REM-HF - Remote monitoring: an evaluation of implantable devices for management of heart failure patientsPresented at the ESC congress 2016 by: Martin R. ConclusionBoth low doses of rivaroxaban showed to be effective in reducing cardiac events. The approval is based on the recently presented SELECT CV outcomes trial, which showed that once weekly subcutaneous semaglutide 2. If delaying surgery is not possible, it should be performed without cessation of APT. Reducing ASCVD risk is a challenge, especially in patients with residual risk despite various therapies. Expanding focus for cardiologists The diabetic patient and cardiovascular outcomes. How can the discordant clinical outcomes with EPA alone vs. The HELIOS trials, a groundbreaking phase 3 program, are investigating the potential of vutrisiran, an RNA interference (RNAi) therapy, to combat both hereditary and wild-type ATTR amyloidosis. 006 Introduction and methods Background SGLT2 inhibitors …. What is the best antithrombotic treatment post-PCI? ESC Congress 2023 Pascal Burger presents the results of a subanalysis of the REDUCE-IT trial, which examined the treatment effects of icosapent ethyl in subgroups. Elderly patients with type 2 diabetes (T2DM) are at increased risk of hypoglycemia [1]. Taylor Swift and Beyoncé raked in concert money in 2023 and this year, superstars Olivia Rodrigo and Bad Bunny are taking the stage as Americans are …. This course consists of 3 episodes. These findings provide support for a scalable. UC San Diego Physician Assessment and Clinical Education (PACE) Program. Earn CME credits while learning at your own pace. AHA 2023 Deepak Gupta talks about the novel insights that the CARDIA-SSBP study provides on the effects of dietary sodium reduction on blood pressure. PACE is a provider of accredited CE/CME activities for various specialties and topics. 2024 Feb 15:S0002-8703(24)00033-4 [Online ahead of print].